Ozkars, M. Y.Keskin, O.Tokur, M.Ulasli, M.Gogebakan, B.Ciralik, H.Kucukosmanoglu, E.2024-09-182024-09-1820180301-05461578-1267https://doi.org/10.1016/j.aller.2017.07.003https://hdl.handle.net/20.500.12483/7780Background: Corticosteroids are used in the treatment of asthma. The aim of this study was to determine the efficacy of anti-IgE and anti-TNF alpha as asthma treatments. Methods: A mouse model of chronic asthma was developed. The fluticasone group was exposed to fluticasone and the anti-IgE and anti-TNF groups were administered anti-IgE or anti-TNF. IL-4, and IgE levels were measured, and histological analysis, pathological analysis and miRNA-126, miRNA-133a analyses were applied. Results: The cell concentration in the BAL fluid decreased in all the treatment groups. The rate of perivascular and peribronchial cell infiltration decreased in the lung in the high-dose anti-IgE and anti-TNF groups. Smooth muscle thickness decreased in the lung tissue in the low dose anti-IgE and anti-TNF groups. Bronchial wall thickness decreased in the lung tissue in the fluticasone + antidgE group. The IL-4 level in BAL fluid decreased in the high-dose anti-IgE, fluticasone + anti-IgE and anti-TNF groups. IgE levels increased in the BAL fluid in the high dose anti-IgE and anti-TNF groups. The lymphocyte level increased in the BAL fluid in the high-dose anti-IgE group. The macrophage level decreased in the BAL fluid in the anti-TNF group. The relative expression of miRNA-126 increased in all groups. The relative expression of miRNA-133a decreased in the placebo and fluticasone groups. The relative expression of miRNA133a increased in the low-dose anti-IgE, high-dose anti-IgE, fluticasone + anti-IgE and anti-TNF groups. Conclusions: The results showed that anti-IgE is successful as a treatment. Fluticasone + antiIgE and anti-TNF were seen to be superior to other therapeutic modalities when used for prophylaxis. (C) 2017 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.eninfo:eu-repo/semantics/closedAccessAnti-IgEAnti-TNFAsthmaFluticasoneIgEIL-4Lung histopathologymiRNA-126miRNA-133aArticle46322623410.1016/j.aller.2017.07.003291913612-s2.0-85035191874Q3WOS:000430786300004Q4